Advertisement

Breathlessness in cancer patients

Published:April 23, 2008DOI:https://doi.org/10.1016/j.ejca.2008.03.004

      Abstract

      Breathlessness (or dyspnoea) is a common symptom experienced by cancer patients. It may be iatrogenic and is often caused or aggravated by co-morbidity. Recent studies have elucidated the neural and chemical controls of breathing which may be involved in the production of dyspnoea. A rational approach involves making a diagnosis of aetiology and treating reversible causes wherever possible. The main approaches for palliation of dyspnoea include anti-cancer treatments; drugs; oxygen and airflow; non-medical approaches. Further research is needed to clarify the best pharmacological regimens and the place of more invasive interventions.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dudgeon D.J.
        • Kristjanson L.
        • Sloan J.A.
        • Lertzman M.
        • Clement K.
        Dyspnea in Cancer Patients: Prevalence and Associated Factors.
        J Pain Symptom Manage. 2001; 21: 02-95
        • Hauser C.A.
        • Stockler M.R.
        • Tattersall M.H.N.
        Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review.
        Support Care Cancer. 2006; 14: 999-1011
        • Ahmedzai S.H.
        Cough in cancer patients.
        Pulm Pharmacol Therap. 2004; 17: 415-423
        • Gillette M.A.
        • Schwartzstein R.M.
        Mechanisms of dyspnoea.
        in: Ahmedzai S.H. Muers M. Supportive Care in Respiratory Disease. OUP, Oxford2005: 93-122 (Chap 6)
        • von Leupold A.
        • Dahme B.
        Cortical substrates for the perception of dyspnoea.
        Chest. 2005; 128: 345-354
        • Rock L.L.K.
        • Schwartzstein R.M.
        Mechanisms of dyspnea in chronic lung disease.
        Curr Opin Support Palliat Care. 2007; 1: 102-108
        • Piepoli M.F.
        • Kaczmarek A.
        • Francis D.P.
        • Davies C.L.
        • et al.
        Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure.
        Circulation. 2006; 114: 126-134
        • Parsons L.M.
        • Egan G.
        • Liotti M.
        • Brannan S.
        • et al.
        Neuroimaging evidence implicating cerebellum in the experience of hypercapnia and hunger for air.
        PNAS. 2001; 4: 2041-2046
        • Manzke T.
        • Guenther U.
        • Ponimaskin E.G.
        • Haller M.
        • et al.
        5HT4A receptors avert opiods-induced breathing depression without loss of analgesia.
        Science. 2003; : 226-229
        • Muers M.F.
        Opioids for dyspnoea.
        Thorax. 2002; 57: 922-923
        • Yorke J.
        Dyspnoea and pain: an interesting analogy.
        J Clin Nurs. 2008; : 841-842
        • Reid M.B.
        • Lannergren J.
        • Westerblad K.
        Respiratory and limb muscle weakness induced by tumour necrosis factor – alpha.
        Am J Respir Crit Care Med. 2002; 166: 479-484
        • Tanaka K.
        • Akewchi T.
        • Okuyama T.
        • Nishiwaki Y.
        • Uchitomi Y.
        Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale.
        Brit J Cancer. 2000; 82: 800-805
        • Vora V.A.
        • Ahmedzai S.H.
        Pulse oximetry in supportive and palliative care.
        Support Care Cancer. 2004; 12: 758-761
      1. Hoskin P, Ahmedzai SH. Assessment and management of respiratory symptoms of malignant disease. In: Ahmedzai SH, Muers M, editors. Supportive Care in Respiratory Disease. Oxford: OUP; 2005. p. 463–86. Chap 30.

      2. Kvale PA, Selecky PA, Prakash UBS. Palliative care in lung cancer. ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007:132; 368S-403S.

        • Saffran L.
        • Ost D.E.
        • Fein A.M.
        • Schiff M.J.
        Outpatient pleurodesis of malignant pleural effusions using a small-bore Pigtail catheter.
        Chest. 2000; 118: 417-421
        • Neragi-Miandoab S.
        Surgical and other invasive approaches to recurrent pleural effusion with malignant etiology.
        Support Care Cancer. 2008;
        • Navigante A.H.
        • Cerchietti L.C.A.
        • Castro M.A.
        • Lutteral M.A.
        • Cabalar M.E.
        Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnoea perception in patients with advanced cancer.
        J Pain Symptom Manage. 2006; 31: 38-47
        • Jennings A.-L.
        • Davies A.N.
        • Higgins J.P.T.
        • Gibbs J.S.R.
        • Broadley K.E.
        A systematic review of the use of opioids in the management of dyspnoea.
        Thorax. 2002; 57: 939-944
        • Abernethy A.P.
        • Currow D.C.
        • Frith P.
        • Fazekas B.S.
        Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea.
        BMJ. 2003; 327: 523-528
        • Poole P.J.
        • Vele A.G.
        • Black P.N.
        The efect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 1998; 157: 1877-1880
        • Clemens K.E.
        • Klaschik E.
        Symptomatic therapy of dyspnoea with strong opioids and its effect on ventilation in palliative care patients.
        J Pain Symptom Manage. 2007; 33: 473-481
        • Dahan A.
        • Yassen A.
        • Romberg R.
        • Sarton E.
        • et al.
        Buprenorphine induces ceiling in respiratory depression but not in analgesia.
        Brit J Anaesthesia. 2006; 96: 627-632
        • Nishino T.
        • Ide T.
        • Sudo T.
        • Sato J.
        Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnoea.
        Am J Respir Crit Care Med. 2000; 161: 1963-1967
        • Moosavi S.H.
        • Binks P.A.
        • Lansing R.W.
        • Topulos G.P.
        • Banzett R.B.
        • Schwartzstein R.M.
        Effect of inhaled furosemide on air hunger induced in healthy humans.
        Respiratory Physiology & Neurobiology. 2007; 156: 1-8
        • Kohara H.
        • Ueoka H.
        • Aoe K.
        • Maeda T.
        • et al.
        Effect of nebulized furosemide in terminally ill cancer patients with dyspnoea.
        J Pain Symptom Manage. 2003; 26: 962-967
        • Booth S.
        • Anderson H.
        • Swannick M.
        • Wade R.
        • et al.
        The use of oxygen in the palliation of breathlessness.
        Resp Med. 2004; 98: 66-77
        • Ahmedzai S.H.
        • Laude E.
        • Robertson A.
        • Troy G.
        • Vora V.
        A double-blind, randomised, controlled Phase II trial of Heliox28 gas mixture in lung cancer patients with dyspnoea on exertion.
        Brit J Cancer. 2004; 90: 366-371
        • Schwartzstein R.M.
        • Lahive K.
        • Pope A.
        • Weinberger S.E.
        • Weiss J.W.
        Cold facial stimulation reduces breathlessness induced in normal subjects.
        Am Rev Respir Dis. 1987; 136: 58-61
        • MacLeod R.
        Psychosocial therapies.
        in: Ahmedzai S.H. Muers M. Supportive Care in Respiratory Disease. OUP, Oxford2005: 229-238 (Chap 13)
        • Morita T.
        • Tsunoda A.H.
        • Inoue S.
        • Chihara S.
        Contributing factors to physical symptoms in terminally-ill cancer patients.
        J Pain Symptom Manage. 1999; 18: 338-346
        • Morita T.
        • Chinone Y.
        • Ikenaga M.
        • Miyoshi M.
        • et al.
        Ethical validity of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan.
        J Pain Symptom Manage. 2005; 30: 308-319
        • Bennett M.
        • Lucas V.
        • Brennan M.
        • Hughes A.
        • et al.
        Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care.
        Palliat Med. 2002; 16: 369-374